Faruqi and Faruqui, LLP Logo
Share this page

Roche Holding AG (RHHBY)

Other OTC:RHHBY

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Roche Holding AG To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Roche Holding AG (“Roche” or the “Company”) (Other OTC:RHHBY) of the August 7, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Roche stock or options between March 2, 2017 and June 5, 2017 and would like to discuss your legal rights, please fill out the form below.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

The lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all those who purchased Roche securities between March 2, 2017 and June 5, 2017 (the “Class Period”).  The case, Biondolillo v. Roche Holding AG et al., No. 3:17-cv-04056 was filed on June 6, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the combination of the Company’s breast cancer drug, Perjeta and its older treatment, Herceptin, is only marginally more effective than Herceptin alone in preventing breast cancer; and (2) as a result, the Company’s statements about its business, operations and prospects were materially false and misleading and/or lacked a reasonable basis.

Specifically, on June 5, 2017, the Company issued a press release entitled, “APHINITY study shows Roche’s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer.”  Following this release, Financial Times published an article stating that oncologists may refrain from using the Company’s new combination of Perjeta and Herceptin going forward as a result of Roche’s latest trial results.  Additionally, Bloomberg Quint published an article stating that Roche’s latest trial results do not justify switching a majority of patients to Roche’s new combination treatment.  Lastly, Fox Business published an article that discussed the concerns of medical professionals regarding Roche’s trial results.

On this news, Roche’s share price fell from $34.37 on June 2, 2017 to a closing price of $32.61 on June 5, 2017—a $1.76 or a 5.12% drop.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Roche Holding AG (RHHBY)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 06/07/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.